StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
IRONBullishIndustry Newsnews
High materiality8/10

Disc Medicine's DISC-3405 Raises Hepcidin in PV, Signals Pivotal Path Ahead

Sep 9, 2026, 7:43 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive Phase 2 readouts with clear clinical benefits (phlebotomy reduction, hematocrit control) may raise expectations for pivotal trials and potential partnerships or licensing milestones, likely prompting a near-term stock uptick; risk remains due to small phase size and regulatory uncertainties.

AI summary

What happened, with direct paths to the underlying reporting

Disc Medicine announced positive RESTORE-PV results for DISC-3405, increasing hepcidin and lowering serum iron, enabling reduced phlebotomy and controlled hematocrit in polycythemia vera. The company also highlighted additional MF data (DISC-0974) and plans year-end updates, signaling near-term catalysts toward pivotal trials in PV and MF.

  • RESTORE-PV results show DISC-3405 raises hepcidin and lowers iron in PV.
  • Phlebotomy reductions: mean 4.0 to 0.6 events in 26 weeks (p<0.0001).
  • 61.5% became phlebotomy-free through 26 weeks; 77.8% during maintenance.
  • SOHO presentation to feature data; year-end updates planned for DISC-3405 and MF program.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event